Design and Evaluate 12 Week Group Therapy Intervention for HIV+ Methamphetamine Users and Deliver It Within an HIV/AIDS Primary Care Setting. - 1 - Tabular View

Tracking Information

First Received Date ^ICMJE

November 3, 2005

Last Updated Date

November 3, 2005

Start Date ^ICMJE

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Craving
Medication compliance
Addiction severity
Psychiatric interview
Sex-risk behavior

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

No Changes Posted

Current Secondary Outcome Measures ^ICMJE

Depression
Quality of Life

Original Secondary Outcome Measures ^ICMJE

Same as current

Descriptive Information

Brief Title ^ICMJE

Design and Evaluate 12 Week Group Therapy Intervention for HIV+ Methamphetamine Users and Deliver It Within an HIV/AIDS Primary Care Setting. - 1

Official Title ^ICMJE

Behavioral Therapy Development for Methamphetamine Abuse

Brief Summary

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Detailed Description

Study Phase

Phase II

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment

Condition ^ICMJE

Behavior Therapy
Methamphetamine

Intervention ^ICMJE

Behavioral: Behavior Therapy

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Not yet recruiting

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Inclusion Criteria:

HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
Willing to give informed consent and comply with study procedures;
Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
Diagnosed with current methamphetamine abuse as determined by MINI; and
Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

Unwilling to give, or withdrawal of, informed consent;
Inability to understand nature of study;
A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
Current suicidal ideation or suicide attempt within the past 3 months; and
Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Gender

Male

Ages

18 Years to 65 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00249678

Responsible Party

Study ID Numbers ^ICMJE

NIDA-18075-1, R21-18075-1

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

University of California, Los Angeles

Investigators ^ICMJE

Principal Investigator:

James Peck, Other

University of California, Los Angeles

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

November 2005

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP